December 27, 2021 – Quidel Corp. (San Diego, CA) and Ortho Clinical Diagnostics Holdings plc (Raritan, NJ) have entered into a definitive agreement in which Quidel will acquire Ortho, one of the world’s largest in vitro diagnostics companies, for $24.68 per share of common stock using a combination of cash and newly issued shares in the combined company for an equity value of approximately $6 billion. The transaction is expected to close during the first half of fiscal year 2022, subject to customary closing conditions.
The combined organization will unite technologies and platforms to benefit customers with expanded access to clinical chemistry, immunoassay, molecular diagnostics, immunohematology, donor screening and point-of-care diagnostics offerings.